Clinical Trials

121 enrolled

Lymphoma, Non-Hodgkin

NCT06252675 2026-04-20

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT07453095 2026-04-17

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

Phase 1 Not yet recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT07528352 2026-04-17

REBEL

12 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07003295 2026-04-16

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT06634589 2026-04-15

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

Phase 1 Not yet recruiting

Lymphoma, Non-Hodgkin

NCT07444710 2026-04-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Ann Arbor Stage II Mantle Cell Lymphoma

NCT05798156 2026-04-08

R-Pola-Glo

125 enrolled

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

211 enrolled

Lymphoma, Non-Hodgkin

NCT03075696 2026-04-03

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 2 FDA

Lymphoma, Non-Hodgkin

NCT05533775 2026-04-03

iMATRIX GLO

65 enrolled

Recurrence

NCT07200375 2026-04-03

GlofitReal

Recruiting

300 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06084936 2026-04-02

GLOBRYTE

Phase 3 Recruiting

182 enrolled

Lymphoma

NCT06624085 2026-04-02

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma

NCT06806033 2026-03-31

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07502872 2026-03-31

TPG

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05896163 2026-03-27

MAPtivate-6

Phase 1 Active not recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06192888 2026-03-27

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

39 enrolled

Lymphoma, Mantle-Cell

NCT06481826 2026-03-27

Glofitamab in Chinese Patients With R/R DLBCL

Recruiting

20 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT04889716 2026-03-18

CAR-T Followed by Bispecific Antibodies

42 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

NCT04703686 2026-03-16

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Phase 2 Completed

67 enrolled

Lymphoma, Mantle-Cell

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

47 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

200 enrolled

Lymphoma, B-Cell

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

498 enrolled

Lymphoma, Non-Hodgkin

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

46 enrolled

Lymphoma

NCT06558604 2026-02-11

GLOASIS

100 enrolled

Lymphoma, Mantle-Cell

NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

255 enrolled

Phase EARLY_PHASE1 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

27 enrolled

Lymphoma, Mantle-Cell

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Lymphoma, B-Cell

NCT07326371 2026-01-08

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

24 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

LymphoidOther hematologic neoplasm

70 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06054776 2026-01-05

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT05364424 2025-12-01

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1 Completed

43 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06765317 2025-11-26

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Dendritic Cell Sarcoma, Interdigitating

NCT06534437 2025-09-29

JASPIS-01

178 enrolled

Aggression, Lymphoma, Non-Hodgkin, Recurrence

NCT06670105 2025-09-17

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Phase 2 Withdrawn

Lymphoma, B-Cell

NCT06665217 2025-08-14

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

22 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07012980 2025-06-10

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06552572 2025-05-21

Glory